PURPOSE: Little is known about the prevalence of combined anxiety and depressive symptoms (CADS) in breast cancer patients. Purpose was to evaluate for differences in demographic and clinical characteristics and quality of life (QOL) prior to breast cancer surgery among women classified into one of four distinct anxiety and/or depressive symptom groups. METHODS: A total of 335 patients completed measures of anxiety and depressive symptoms and QOL prior to and for 6 months following breast cancer surgery. Growth Mixture Modelling (GMM) was used to identify subgroups of women with distinct trajectories of anxiety and depressive symptoms. These results were used to create four distinct anxiety and/or depressive symptom groups. Differences in demographic, clinical, and symptom characteristics, among these groups were evaluated using analyses of variance and Chi square analyses. RESULTS: A total of 44.5% of patients were categorized with CADS. Women with CADS were younger, non-white, had lower performance status, received neoadjuvant or adjuvant chemotherapy, had greater difficulty dealing with their disease and treatment, and reported less support from others to meet their needs. These women had lower physical, psychological, social well-being, and total QOL scores. Higher levels of anxiety with or without subsyndromal depressive symptoms were associated with increased fears of recurrence, hopelessness, uncertainty, loss of control, and a decrease in life satisfaction. CONCLUSIONS: Findings suggest that CADS occurs in a high percentage of women following breast cancer surgery and results in a poorer QOL. Assessments of anxiety and depressive symptoms are warranted prior to surgery for breast cancer.
PURPOSE: Little is known about the prevalence of combined anxiety and depressive symptoms (CADS) in breast cancerpatients. Purpose was to evaluate for differences in demographic and clinical characteristics and quality of life (QOL) prior to breast cancer surgery among women classified into one of four distinct anxiety and/or depressive symptom groups. METHODS: A total of 335 patients completed measures of anxiety and depressive symptoms and QOL prior to and for 6 months following breast cancer surgery. Growth Mixture Modelling (GMM) was used to identify subgroups of women with distinct trajectories of anxiety and depressive symptoms. These results were used to create four distinct anxiety and/or depressive symptom groups. Differences in demographic, clinical, and symptom characteristics, among these groups were evaluated using analyses of variance and Chi square analyses. RESULTS: A total of 44.5% of patients were categorized with CADS. Women with CADS were younger, non-white, had lower performance status, received neoadjuvant or adjuvant chemotherapy, had greater difficulty dealing with their disease and treatment, and reported less support from others to meet their needs. These women had lower physical, psychological, social well-being, and total QOL scores. Higher levels of anxiety with or without subsyndromal depressive symptoms were associated with increased fears of recurrence, hopelessness, uncertainty, loss of control, and a decrease in life satisfaction. CONCLUSIONS: Findings suggest that CADS occurs in a high percentage of women following breast cancer surgery and results in a poorer QOL. Assessments of anxiety and depressive symptoms are warranted prior to surgery for breast cancer.
Authors: Annette L Stanton; Patricia A Ganz; Julia H Rowland; Beth E Meyerowitz; Janice L Krupnick; Sharon R Sears Journal: Cancer Date: 2005-12-01 Impact factor: 6.860
Authors: Chiara Nosarti; Jonathan V Roberts; Timothy Crayford; Kwame McKenzie; Anthony S David Journal: J Psychosom Res Date: 2002-12 Impact factor: 3.006
Authors: B E Compas; M F Stoll; A H Thomsen; G Oppedisano; J E Epping-Jordan; D N Krag Journal: Breast Cancer Res Treat Date: 1999-04 Impact factor: 4.872
Authors: J E Epping-Jordan; B E Compas; D M Osowiecki; G Oppedisano; C Gerhardt; K Primo; D N Krag Journal: Health Psychol Date: 1999-07 Impact factor: 4.267
Authors: Marianna Kyranou; Kathleen Puntillo; Bradley E Aouizerat; Laura B Dunn; Steven M Paul; Bruce A Cooper; Claudia West; Marylin Dodd; Charles Elboim; Christine Miaskowski Journal: J Appl Biobehav Res Date: 2014-06
Authors: Kristin Härtl; Jutta Engel; Peter Herschbach; Hans Reinecker; Harald Sommer; Klaus Friese Journal: Psychooncology Date: 2010-02 Impact factor: 3.894
Authors: Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Doreen Koretz; Kathleen R Merikangas; A John Rush; Ellen E Walters; Philip S Wang Journal: JAMA Date: 2003-06-18 Impact factor: 56.272
Authors: Carmen W Sullivan; Heather Leutwyler; Laura B Dunn; Bruce A Cooper; Steven M Paul; Jon D Levine; Marilyn Hammer; Yvette P Conley; Christine A Miaskowski Journal: J Pain Symptom Manage Date: 2017-08-31 Impact factor: 3.612
Authors: Carmen Ward Sullivan; Heather Leutwyler; Laura B Dunn; Bruce A Cooper; Steven M Paul; Yvette P Conley; Jon D Levine; Christine A Miaskowski Journal: Eur J Oncol Nurs Date: 2017-04-26 Impact factor: 2.398
Authors: Laura Q Rogers; Kerry S Courneya; Philip M Anton; Steven Verhulst; Sandra K Vicari; Randall S Robbs; Edward McAuley Journal: Psychooncology Date: 2016-09-06 Impact factor: 3.894
Authors: Robert Knoerl; Anita Giobbie-Hurder; Timothy S Sannes; Anees B Chagpar; Deborah Dillon; Laura Stewart Dominici; Elizabeth S Frank; Mehra Golshan; Anne McTiernan; Esther Rhei; Sara M Tolaney; Eric P Winer; Rachel L Yung; Melinda L Irwin; Jennifer A Ligibel Journal: Support Care Cancer Date: 2021-10-14 Impact factor: 3.603